Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5237763 | 0.97 | SLC6A2 (0.47) | SLC6A2SLC6A4NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL16673562 | 0.97 | SLC6A2 (0.47) | SLC6A2SLC6A4NOS3NOS1NOS2 | |
| SCHEMBL23377075 | 0.86 | SLC6A4 (0.49) | SLC6A2SLC6A4NOS3NOS1NOS2 | |
| SCHEMBL13770853 | 0.86 | SLC6A2 (0.44) | SLC6A2SLC6A4NOS3NOS1NOS2 | |
| SCHEMBL1484817 | 0.85 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL64736 | 0.85 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5033271 | 0.85 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3405821 | 0.84 | SLC6A4 (0.41) | SLC6A2SLC6A4NOS3NOS1NOS2 | |
| Bromide SCHEMBL1306907 | 0.83 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL3558297 | 0.83 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111819176-B | 4-azaindole compounds | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | claimed |
| CN-116332807-A | Production process of 3- (trifluoromethyl sulfonyl) -2-methyl naphthoate | 安徽秀朗新材料科技有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-112898170-B | Preparation method of acid diffusion inhibitor and photoresist composition | 宁波南大光电材料有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-112898170-A | Preparation method of acid diffusion inhibitor and photoresist composition | 宁波南大光电材料有限公司 | 2021-06-04 | — | — | CN | claimed |
| EP-2271936-B1 | IN VITRO METHOD TO DETERMINE WHETHER A DRUG CANDIDATE ACTIVE AGAINST A TARGET PROTEIN IS ACTIVE AGAINST A VARIANT OF SAID PROTEIN | VALNEVA (FR) | 2015-05-06 | — | — | EP | claimed |
| CN-119409647-B | Preparation and application of 3-amino-pyrazine-2-amide derivative targeting FGFR | 重庆医科大学 | 2026-05-12 | — | — | CN | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260049088-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4688782-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12545668-B2 | Cyclic amine derivative as agent for promoting advillin function, and novel cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20250333396-A1 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | CELATOR PHARMACEUTICALS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-5530009-A | TREATING ASTHMA | ELI LILLY AND COMPANY (US) | 1996-06-25 | — | — | US | disclosed |
| WO-1996001819-A1 | HETEROCYCLIC TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-01-25 | — | — | WO | disclosed |
| EP-0693489-A1 | Heterocyclic tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0481288-B1 | 1-Phenylpiperid-4-ylamines and drugs containing them | BASF AG (DE) | 1995-07-26 | — | — | EP | disclosed |
| US-5391556-A | Thrombin inhibitors | KARL THOMAE GMBH (DE) | 1995-02-21 | — | — | US | disclosed |
| US-5175174-A | PHENYLPIPERIDINYLAMINES AND DRUGS CONTAINING THESE | BASF AKTIENGESELLSCHAFT (DE) | 1992-12-29 | — | — | US | disclosed |
| EP-0481288-A2 | 1-Phenylpiperid-4-ylamines and drugs containing them | BASF Aktiengesellschaft (DE) | 1992-04-22 | — | — | EP | disclosed |
| US-4041032-A | ANTIEMATICS, GASTRIC MOTILITY STIMULANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545668-B2 | Cyclic amine derivative as agent for promoting advillin function, and novel cyclic amine derivative and pharmaceutical use thereof | SSB, TLR9, C5AR2 | SLC6A2 722/4885SLC6A4 2613/4885NOS3 737/4885 |
| US-20250333396-A1 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | ATR, CHEK2, CHEK1 | SLC6A2 4738/4885SLC6A4 4746/4885NOS3 2984/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | SLC6A2 2490/4885SLC6A4 1101/4885NOS3 2180/4885 |
| US-20260049088-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | SRD5A2, CBR1, SRD5A1 | SLC6A2 278/4885SLC6A4 487/4885NOS3 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.